AbCellera
@AbCelleraBio
Followers
4,971
Following
91
Media
200
Statuses
383
We discover & develop antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders
Vancouver, British Columbia
Joined January 2016
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Taylor
• 382867 Tweets
#TENxFireworkMeetandGreet
• 215189 Tweets
TEN X MAYBELLINE EVENT
• 202689 Tweets
Yankees
• 96501 Tweets
期日前投票
• 45229 Tweets
APT NUMBER ONE
• 26131 Tweets
ML IN SINGAPORE
• 23162 Tweets
#ガルアワ2024AW
• 18593 Tweets
TIM MCGRAW
• 14443 Tweets
#NOAHnoHAKOBUNE
• 13296 Tweets
#SarfarazKhan
• 10660 Tweets
Today,
@JustinTrudeau
announced that the Canadian Govt will spend $192M on developing COVID-19 vaccine & treatments.
@AbCelleraBio
is deeply honored to receive this support for our efforts in discovering & developing an antibody treatment for COVID-19.
3
23
100
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
6
16
97
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
Preprint data shows LY-CoV1404 binds and neutralizes all currently known circulating SARS-CoV-2 variants of concern:
4
28
85
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
1
11
87
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
2
9
85
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
5
16
76
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
3
17
74
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
4
14
74
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
5
10
71
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
1
16
73
Today, PM Trudeau and Minister Bains announced AbCellera's project with the Strategic Innovation Fund (SIF). We are proud to have the support of the Government of Canada to combat COVID-19 & help build Canadian capabilities to fight future pandemics.
1
15
68
AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment.
#antibody
#COVID19
#drugdiscovery
2
14
68
We are honoured to announce AbCellera Founder & CEO Carl Hansen as 2021
@BloomBurton
Award winner. Each year, Bloom Burton recognizes an individual who made the greatest contribution to our healthcare industry in the previous year.
20
6
66
Congratulations to our partner,
@AbderaTx
, on receiving FDA clearance for its IND application for ABD-147, an antibody-based precision radiotherapeutic targeting small cell lung cancer and large cell neuroendocrine carcinoma.
3
12
66
We have broken ground on Phase II of our state-of-the-art tech campus in Vancouver, BC. Thank you to our development partner,
@BeedieBuilt
, and everyone who worked to make this facility possible.
2
7
62
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
0
7
64
AbCellera is 5th on the
@globebusiness
list of top growing Canadian companies in 2021. Read about how we’re growing our dedicated and passionate team of AbCellerites.
#TopGrowing21
1
9
62
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
1
8
62
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
5
11
57
Congratulations to our CEO Dr. Carl Hansen, who has been named one of the Top 50 Healthcare Technology CEOs of 2021. A big round of applause to all of the awardees for their outstanding leadership and significant contributions in healthcare technology.
1
0
61
.
@CellReports
publishes data on bebtelovimab, the second AbCellera-discovered COVID-19 antibody treatment. This potent antibody therapy for COVID-19 is effective against all currently known variants of concern, including Omicron and the BA.2 subvariant.
2
14
55
AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19
0
16
57
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
2
6
54
Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
1
8
54
We're proud to be recognized as the Life Sciences Company of the Year by
@lifesciences_bc
. Congratulations to all of the winners, whose drive and creativity contribute to BC’s strong life sciences community.
4
12
52
We’re excited to announce that our team in Boston, previously known as TetraGenetics, is now AbCellera Boston. Together we’re tackling some of the most difficult challenges in antibody discovery to bring treatments to patients faster.
2
2
52
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
1
7
51
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
10
3
48
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
1
6
49
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
3
8
50
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
1
9
47
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
1
7
46
AbCellera continues expansion and strengthens future pandemic preparedness by building a first-of-its-kind Canadian GMP manufacturing facility, which will support our partners' clinical development of antibody therapies for an array of medical conditions.
0
13
45
Develop new T-cell engagers faster by combining a diverse, developable, and validated panel of CD3-binding antibodies with a clinically-validated bispecific engineering platform. Learn more at
@Keystonesymp
’s Multispecific Immune Cell Engagers for Cancer Immunotherapy.
0
3
44
AbCellera presents data on T-cell engagers against four tumor targets at AACR 2024
2
8
45
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
3
6
43
AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant.
3
9
43
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
0
2
43
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-Beta Superfamily Member for the Treatment of Cancer
2
5
42
The data from the BLAZE-1 study "show that if given early in infection, antibody therapy can keep most patients out of hospitals and can save lives,” -Carl Hansen, CEO AbCellera
2
9
42
It has been a year of incredible achievements for AbCellera! Our CEO Carl Hansen has been named an
@EYCanada
Entrepreneur Of The Year® 2021 Pacific winner. Kudos to the courageous entrepreneurs working hard to do things that have never been done before.
11
3
39
We are excited to welcome our team in Australia, previously known as Channel Bio, under the AbCellera brand. Together we’re tackling some of the most difficult challenges in antibody discovery to bring treatments to patients faster.
1
2
40
Congratulations to Andrew Booth, AbCellera's CFO, who is a recipient of
@globeandmail
's Report on Business 2024 Best Executive Awards.
Canada is at an inflection point. We have an opportunity to build, from the ground up, a life sciences ecosystem that will make our communities
11
3
40
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
2
4
39
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
1
5
39
Congratulations to
@ArsenalBio
, who in April announced the start of Phase 1/2 for AB-2100 in renal cell carcinoma.
3
5
41
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
0
2
39
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
0
10
34
AbCellera Announces Pricing of Initial Public Offering
4
9
39
We’re proud to be ranked 30th on
@DeloitteTMT
’s
#Fast500
list of growing tech companies in North America!
3
3
38
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
0
4
37
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
0
2
38
Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
0
4
36
Opinion: We have antibody therapies for COVID-19: They save lives, now use them
0
22
37
AbCellera is mobilizing to respond to the Wuhan coronavirus outbreak as part of the DARPA P3 program.
#AbCellera
#antibodytherapeutic
#Wuhan
#Wuhancoronavirus
#coronavirus
#2019nCoV
#antibody
#singlecell
0
13
35
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
0
4
37
AbCellera Announces Virtual Presentations at Investor Conferences in November
4
4
34
Combine a diverse, developable, and validated panel of CD3-binding antibodies with a clinically-validated
#bispecific
engineering platform to develop new T cell engagers for cancer. See the data at
#AACR22
.
0
7
35
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
0
4
36
Within 3 days, AbCellera had inspected 5 million cells and found 500 different antibodies that stuck to the “spike” protein of the virus, potentially blocking it. Any one of these antibodies could be a cure for others infected.
@techreview
#COVID19
1
17
31
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
0
3
35
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
1
3
35
AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform
2
11
34
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
0
2
35
The AbCellera-discovered antibody LY-CoV1404 may be a long-term complement to COVID-19 vaccines to address SARS-CoV-2 variants.
0
10
32
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
6
3
34
AbCellera to Report Full Year 2022 Business Results on February 21, 2023
0
1
32
AbCellera to present data on T-cell engager platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on November 11, 2022.
1
4
34
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
0
5
35
Together with the Governments of Canada and British Columbia, AbCellera is co-investing to advance drug development capabilities and infrastructure that will bring new medicines to patients, create jobs, and fuel innovation. Read the full press release:
0
2
32
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
0
4
34
See the latest data on T-cell engager programs for multiple tumor targets, including PSMA and challenging peptide-MHCs, at
#AACR2024
.
1
7
34
There’s an opportunity to widen the therapeutic window of T-cell engagers by reducing cytokine release. See data on our CD3 x PSMA program at Festival of Biologics on April 15 - 17 to learn more.
#FOBUSA
1
2
33
Learn about how to widen the therapeutic window for T-cell engagers using platform technologies. See our CD3 x PSMA case study at Antibody Engineering & Therapeutics
#AETEU
1
2
34
AbCellera-Discovered Antibody, Bamlanivimab (LY-CoV555), Granted Interim Authorization by Health Canada as a Treatment for
#COVID19
:
0
6
32
Bamlanivimab is now authorized in two antibody therapy regimens to treat COVID-19 in patients at high risk for hospitalization
0
4
32
AbCellera is thrilled to be featured as one of the Fierce 15 biotech companies of 2020! Thank you to
@FierceBiotech
for recognizing us and congratulations to all the companies in this year's impressive line up.
#Fierce15
0
3
32
ICYMI: “Maybe what surprised me was the massive impact that that could have in such a short time.”
Our CEO Carl Hansen spoke on the
#RBCDisruptors
podcast about bringing therapies to patients, faster.
0
3
32
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
1
2
31
Join our Founder and CEO Carl Hansen as he chats with experts in the field about accelerating
#drugdevelopment
at the
@LongwoodLeaders
Spring 2023 MIT Conference.
#LongwoodHealthcareLeaders
0
2
28
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
2
1
30
Multipass membrane proteins can be hard-to-make and hard-to-hit. Find out how an integrated technology stack makes milligram amounts of protein and drives antibody variety at Antibody Engineering & Therapeutics US.
@AntibodyEngIC
1
3
30
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
1
2
30
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
1
3
30
See us at
#PEGSBoston
to learn about our T cell engagers targeting prostate-specific membrane antigen (PSMA) that showed significantly lower cytokine release compared to clinical benchmarks.
2
4
31
AbCellera has won
@FastCompany
's Innovative Team of the Year award! In collaboration with Eli Lilly & NIAID’s VRC, the team brought the first COVID-19 antibody to clinical trials in <90 days, a process that typically requires 3-6 years.
1
10
29
Learn how the operating system for antibody discovery made it possible for two unique human antibody therapies against SARS-CoV-2 and its variants to enter clinical testing in one year. Join us for Discovery on Target.
#bostonDOT21
2
5
27
Congratulations to our partner,
@invetx
, on its acquisition by Dechra Pharmaceuticals, a global leader in animal health.
2
0
30